Last 48 quarters of trend data · Technology · Hardware, Equipment & Parts
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 26.9% YoY to 16.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 77.05 | — | 30.19 | 37.23 | 27.71 | — | — | 51.53 | 34.99 | — | 67.16 | — | — |
| — | — | — | -27.8% | -20.8% | — | — | — | — | — | -86.4% | — | — | |
| P/S Ratio | 2.07 | 1.92 | 1.68 | 1.53 | 2.20 | 2.59 | 2.85 | 3.07 | 2.02 | 2.51 | 2.64 | 2.66 | 3.41 |
| — | -25.8% | -41.1% | -50.3% | +8.6% | +3.2% | +7.8% | +15.4% | -40.6% | -40.6% | -35.6% | -17.2% | -36.1% | |
| P/B Ratio | 2.79 | 2.63 | 2.34 | 2.08 | 3.03 | 4.03 | 4.61 | 4.40 | 3.12 | 4.07 | 1.40 | 1.46 | 1.78 |
| — | -34.7% | -49.3% | -52.8% | -2.9% | -1.0% | +228.8% | +201.5% | +75.4% | +70.4% | -39.0% | -27.7% | -37.0% | |
| P/FCF | 12.03 | 7.30 | 6.06 | 13.00 | 147.96 | 13.81 | 10.15 | 51.00 | 12.33 | 11.98 | 13.58 | 15.48 | 17.85 |
| — | -47.2% | -40.3% | -74.5% | +1100.0% | +15.3% | -25.2% | +229.5% | -30.9% | -41.4% | -63.0% | -26.9% | — | |
| EV / EBITDA | 13.84 | 16.28 | 16.03 | 12.51 | 19.39 | 22.26 | 19.88 | 23.73 | 15.02 | — | 21.52 | 21.90 | 27.99 |
| — | -26.9% | -19.4% | -47.3% | +29.1% | — | -7.6% | +8.4% | -46.3% | — | -2.1% | +14.7% | -68.3% | |
| EV / EBIT | 31.24 | 50.35 | 16.03 | 27.21 | 18.99 | 66.98 | 358.63 | 33.27 | 24.59 | — | 50.84 | — | 1883.41 |
| — | -24.8% | -95.5% | -18.2% | -22.8% | — | +605.4% | — | -98.7% | — | -40.6% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Mesa Laboratories, Inc.'s operating margin was 4.3% in Q4 2026, down 7.9 pp QoQ and up 1.9 pp YoY. The trailing four-quarter average of 7.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 18.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.5% | 73.2% | 64.2% | 61.5% | 54.6% | 61.8% | 63.3% | 61.3% | 64.0% | 62.1% | 62.5% | 60.4% | 61.6% |
| — | +18.4% | +1.4% | +0.3% | -14.8% | -0.4% | +1.3% | +1.5% | +4.0% | +3.9% | +3.5% | -2.5% | -0.9% | |
| Operating Margin | 7.4% | 4.3% | 12.2% | 7.8% | 5.1% | 2.4% | 9.2% | 6.1% | 9.6% | -460.6% | -0.1% | -0.1% | -1.3% |
| — | +82.4% | +33.2% | +28.2% | -46.4% | +100.5% | +7439.5% | +5472.6% | +831.6% | -49621.8% | -102.0% | -101.7% | +85.6% | |
| Net Margin | 2.7% | -6.5% | 5.6% | 4.1% | 8.0% | -11.4% | -2.7% | 5.9% | 5.8% | -432.2% | 4.0% | -2.3% | -1.1% |
| — | +43.3% | +309.0% | -31.2% | +36.7% | +97.4% | -167.4% | +356.2% | +637.3% | -39423.1% | +376.3% | -204.1% | +62.0% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.9% | -2.2% | 2.0% | 1.4% | 2.9% | -4.5% | -1.1% | 2.2% | 2.3% | -92.9% | 0.5% | -0.3% | -0.1% |
| — | +50.9% | +287.8% | -35.8% | +24.7% | +95.1% | -297.8% | +792.4% | +1727.5% | -59431.3% | +351.6% | -191.6% | +62.2% | |
| ROA | 1.6% | -1.0% | 0.8% | 0.6% | 1.1% | -1.6% | -0.4% | 0.8% | 0.8% | -42.8% | 0.3% | -0.2% | -0.1% |
| — | +41.3% | +323.1% | -25.4% | +42.9% | +96.2% | -222.5% | +498.8% | +1007.1% | -46562.8% | +348.7% | -198.8% | +59.2% | |
| ROIC | 4.9% | 0.8% | 2.0% | 1.0% | 0.7% | 0.3% | 1.2% | 0.7% | 1.2% | -42.7% | -0.0% | -0.0% | -0.1% |
| — | +138.1% | +60.6% | +38.3% | -43.2% | +100.8% | +14256.8% | +8896.5% | +1424.1% | -60514.3% | -101.9% | -101.5% | +85.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Mesa Laboratories, Inc.'s Debt/EBITDA ratio is 10.6x, down from 13.0x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 174.1% YoY to 1.72x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.48 | 0.48 | 0.55 | 1.00 | 1.15 | 1.14 | 1.36 | 1.38 | 1.47 | 1.55 | 0.59 | 0.45 | 0.46 |
| — | -57.4% | -59.4% | -27.5% | -22.0% | -26.5% | +132.7% | +208.5% | +219.5% | +226.7% | +20.0% | -14.9% | -19.2% | |
| Debt / EBITDA | 2.16 | 10.61 | 12.97 | 16.90 | 21.90 | 20.24 | 18.77 | 23.27 | 20.05 | — | 26.29 | 21.59 | 23.87 |
| — | -47.6% | -30.9% | -27.4% | +9.2% | — | -28.6% | +7.8% | -16.0% | — | +66.6% | +32.2% | -61.0% | |
| Current Ratio | 1.72 | 1.72 | 1.94 | 2.02 | 0.66 | 0.63 | 0.71 | 0.70 | 1.94 | 2.47 | 2.68 | 2.96 | 2.93 |
| — | +174.1% | +173.1% | +186.3% | -66.2% | -74.6% | -73.5% | -76.2% | -33.7% | -10.1% | -2.4% | +5.5% | +1.1% | |
| Quick Ratio | 1.72 | 1.72 | 1.45 | 1.44 | 0.47 | 0.47 | 0.53 | 0.51 | 1.37 | 1.73 | 1.86 | 2.13 | 2.03 |
| — | +264.1% | +173.9% | +182.6% | -65.6% | -72.7% | -71.5% | -76.0% | -32.6% | -11.0% | -3.5% | +0.2% | -11.7% | |
| Interest Coverage | — | — | 2.63 | 1.70 | 4.19 | 1.18 | 0.22 | 2.26 | 2.37 | -144.83 | 2.05 | -0.46 | 0.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MLAB stock.
Mesa Laboratories, Inc.'s current P/E is 77.0x. The average P/E over the last 3 quarters is 31.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mesa Laboratories, Inc.'s current operating margin is 7.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mesa Laboratories, Inc.'s business trajectory between earnings reports.